Vivos Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Vivos Therapeutics

08/08/2025 15:57

Vivos Therapeutics Inc VVOS.OQ VVOS.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2025

The Littleton Colorado-based  company is expected to report a 6.7% decrease in revenue to $3.783 million from $4.05 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Vivos Therapeutics Inc is for a loss of 38 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Vivos Therapeutics Inc is $4.23, about 7% below its last closing price of $4.52

This summary was machine generated August 8 at 14:57 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)